Clinical Trials Involving 18F-FLT PET in Breast Cancer
| Treatment | No. of patients | Time point | Outcome |
| Chemotherapy | 14 | Baseline, 6 wk, 30 wk | Early response predicted late response (73) |
| Chemotherapy (FEC) | 14 | 2 at baseline, then 1 at day 7 | 18F-FLT uptake was repeatable in breast tumors, all chemotherapy responders had 18F-FLT PET response (22) |
| Docetaxel | 20 | Baseline, 2 wk | Early reductions were seen in 18F-FLT uptake, which were predictive of clinical response (74) |
| Capecitabine | 6 | Baseline, 1 h | Pharmacodynamic study showing changes in tumor tissue 18F-FLT uptake could be useful as a surrogate measure of TS inhibition (21) |
| Chemotherapy (FEC or FEC-T) | 17 | Baseline, before second cycle | Baseline, after chemotherapy, or change in SUVmax did not correlate with pathologic response to chemotherapy. Baseline SUVmax did correlate with Ki-67 (20) |
| Chemotherapy (AT-CMF) | 15 | Baseline, after 1 cycle, and at the end of chemotherapy | Change in primary tumor SUVmax after 1 cycle was able to predict residual cancer burden (75) |
FEC = 5-fluorouracil, epirubicin, and cyclophosphamide; TS = thymidylate synthase; AT-CMF = adriamycin, docetaxel, cyclophosphamide, methotrexate, 5-fluorouracil.